CRESEMBA POWDER FOR SOLUTION

Country: Կանադա

language: անգլերեն

source: Health Canada

active_ingredient:

ISAVUCONAZOLE (ISAVUCONAZONIUM SULFATE)

MAH:

AVIR PHARMA INC.

ATC_code:

J02AC05

INN:

ISAVUCONAZOLE

dosage:

200MG

pharmaceutical_form:

POWDER FOR SOLUTION

composition:

ISAVUCONAZOLE (ISAVUCONAZONIUM SULFATE) 200MG

administration_route:

INTRAVENOUS

units_in_package:

15G/50G

prescription_type:

Prescription

therapeutic_area:

AZOLES

leaflet_short:

Active ingredient group (AIG) number: 0161030002; AHFS:

authorization_status:

APPROVED

authorization_date:

2018-12-19

SPC

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
CRESEMBA®
Isavuconazole Capsules
Capsules, 100 mg isavuconazole (as isavuconazonium sulfate)
Oral
Isavuconazole for injection
Powder for solution, 200 mg/vial isavuconazole (as isavuconazonium
sulfate)
Intravenous
Antifungal Agent
J02AC05
AVIR PHARMA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.avirpharma.com
Date of Initial Authorization:
December 19, 2018
Date of Revision:
April 12, 2022
Submission Control Number: 256812
CRESEMBA® is a registered trademark of Basilea Pharmaceutica
International AG; used under license by
AVIR Pharma Inc.
_ _
_CRESEMBA (isavuconazole as isavuconazonium sulfate) _
_Page 2 of 49_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Sensitivity/Resistance
04/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.........................................................